Alcon's Clareon PanOptix Pro IOL now available in Canada

PanOptix Pro has demonstrated a 94% light utilization compared to a theoretical maximum utilization of 96% for diffractive optics. Image credit: AdobeStock/Oktay

Alcon’s Clareon Panoptix Pro intraocular lens (IOL) has been approved for cataract patients in Canada.¹ The IOL utilizes the company’s proprietary ENLIGHTEN NXT Optical technology, which delivers the lowest light scatter and highest reported light utilization of any trifocal IOL, according to a news release.

“As the global leader in eye care, we are committed to improving our technologies to advance patient outcomes through rigorous, world-class R&D,” said Rob Scott, vice president of Intraocular Devices, R&D at Alcon, in the release. “Our team looked at hundreds of design options, ultimately landing on a targeted diffractive refinement that helped us recover 50% of light lost to scatter, and reposition it to a beneficial focal point for PanOptix Pro. This allowed for specific enhancements while maintaining the features that have driven the success of PanOptix—the world’s most implanted trifocal IOL.”

PanOptix Pro has demonstrated a 94% light utilization compared to a theoretical maximum utilization of 96% for diffractive optics. This allows for a more uninterrupted light distribution from distance to near, with a 16% increase in optical image contrast between distance and intermediate. The IOL utilizes a clinically-proven low visual disturbance profile, which promotes high spectacle independence and high patient satisfaction.¹

PanOptix Pro is offered at a +2.17 diopter intermediate and a +3.25 diopter near add power. All of Alcon’s IOLs are also available with blue light and UV filtering.¹

“PanOptix has been a cornerstone of my cataract practice for 8 years,” said Rosa Braga-Mele, MD, MEd, FRCSC, professor of ophthalmology at the University of Toronto, in the release. “These lenses have consistently delivered outstanding visual outcomes for my patients – a low visual disturbance profile and a happy patient with greater spectacle independence. So, it’s exciting to see this technology evolve to further meet patients’ visual expectations. Now, with PanOptix Pro, more light utilization and less light scatter [are] possible, empowering both my practice and my patients.”

The PanOptix Pro lens is available in Canada through Alcon in the single-use Clareon AutonoMe preloaded delivery system, with the Clareon Monarch IV delivery system to be made available in early 2026.¹

The lens is also available as the Clareon PanOptix IOL and Clareon Vivity IOL. The PanOptix lens was the first trifocal lens in the US. For Vivity, clinical trials showed a binocular mean uncorrected distance visual acuity of 20/20, a binocular mean uncorrected intermediate visual acuity (26 in) >20/25, and a binocular mean uncorrected near visual acuity (16 in) of 20/32.²

Alcon’s Clareon IOL collection consists of presbyopia-mitigating trifocal lenses and monofocal lenses, both with toric options. Clareon Toric IOLs manage astigmatism with axial and rotational stability. Fibronectin in the lens has been demonstrated to help bind the material to the capsule, anchoring the lens in place to help reduce posterior capsular opacification and improve stability, according to Alcon.²

References:

1. Alcon introduces Clareon PanOptix Pro in Canada, delivering the lowest light scatter of any trifocal IOL. News release. Alcon. June 20, 2025. Accessed June 23, 2025. https://www.businesswire.com/news/home/20250620166312/en/Alcon-Introduces-Clareon-PanOptix-Pro-in-Canada-Delivering-the-Lowest-Light-Scatter-of-any-Trifocal-IOL

2. (Light) to the power of pro. MyAlconProfessionals. Accessed June 23, 2025. https://www.myalcon.com/professional/cataract-surgery/iols/clareon-iol/